Carsten Linnemann, Ph.D.

Chief Executive Officer

Carsten Linnemann, Ph.D.

Chief Executive Officer

Dr. Carsten Linnemann is the President, Chief Executive Officer, and a co-founder of Neogene Therapeutics.

Before Neogene, Dr. Linnemann was active at Kite Pharma as Associate Director, Next Generation T cell Therapies​ and Managing Director of Kite Pharma EU BV. Dr. Linnemann has co-founded several biotech companies, including T-Cell Factory B.V. (acquired by Kite Pharma, Inc. in 2015).

Dr. Linnemann received his Ph.D. with honors in 2013 for his work on engineering T cell immunity by TCR gene transfer in the laboratory of Dr. Ton Schumacher at The Netherlands Cancer Institute. He has co-authored several publications in the field of genetic engineering of T cells and also seminal work on human neo-antigen biology.

Dr. Linnemann is an alumnus of the German Academic Foundation and the Boehringer Ingelheim Fonds – Foundation for Biomedical Research. His professional honors include the Thesis Prize from the Netherlands Society of Gene and Cell Therapy in 2014 and the Antoni van Leeuwenhoek Career Achievement Award from The Netherlands Cancer Institute in 2015.